000281350 001__ 281350
000281350 005__ 20251012002028.0
000281350 0247_ $$2doi$$a10.1016/S1474-4422(25)00285-6
000281350 0247_ $$2pmid$$apmid:40975099
000281350 0247_ $$2ISSN$$a1474-4422
000281350 0247_ $$2ISSN$$a1474-4465
000281350 0247_ $$2altmetric$$aaltmetric:181510840
000281350 037__ $$aDZNE-2025-01097
000281350 041__ $$aEnglish
000281350 082__ $$a610
000281350 1001_ $$aRodrigues, Mark A$$b0
000281350 245__ $$aAssociation between the Edinburgh CT and genetic diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage and recurrent intracerebral haemorrhage: an individual patient data meta-analysis.
000281350 260__ $$aLondon$$bLancet Publ. Group$$c2025
000281350 3367_ $$2DRIVER$$aarticle
000281350 3367_ $$2DataCite$$aOutput Types/Journal article
000281350 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759825613_17320
000281350 3367_ $$2BibTeX$$aARTICLE
000281350 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281350 3367_ $$00$$2EndNote$$aJournal Article
000281350 520__ $$aPatients with lobar intracerebral haemorrhage and MRI biomarkers of cerebral amyloid angiopathy have a greater risk of recurrent intracerebral haemorrhage than patients without these biomarkers. However, access to MRI is limited. We aimed to determine whether the Edinburgh CT-only and CT-APOE diagnostic criteria for cerebral amyloid angiopathy-related lobar intracerebral haemorrhage are associated with recurrent intracerebral haemorrhage.We did a meta-analysis of individual patient data from cohort studies identified at the 2018 International cerebral amyloid angiopathy conference in Lille, France, assessing patients with lobar intracerebral haemorrhage with available diagnostic CT imaging that had been, or could be, rated for the Edinburgh cerebral amyloid angiopathy criteria imaging features, and with follow-up data for recurrent intracerebral haemorrhage and death. Eligible patients were aged 16 years or older with first or recurrent spontaneous lobar intracerebral haemorrhage diagnosed by non-contrast brain CT, with no evidence of an underlying cause other than cerebral small vessel disease. Collaborators provided individual patient-level data. The primary outcome was first recurrent intracerebral haemorrhage occurring at least 30 days after the index event, analysed using primary two-stage (cohort-level) and secondary one-stage (pooled) meta-analyses with multivariable regression models with a competing risk of death, adjusted for age, sex, and CT small vessel disease score. Pooled analyses were adjusted for previous intracerebral haemorrhage, dementia, hypertension, and cohort clustering. All analyses were done in R Project for Statistical Computing (version 4.5.0).We included eight cohorts from Austria, France, Germany, Italy, the UK, and the USA, with 1705 eligible patients for the CT-only criteria. In the primary two-stage meta-analysis of the CT-only criteria (562 patients from three European cohorts, median age 76 years [IQR 68-82], 282 [50%] female and 280 [50%] male), 69 patients had a recurrent intracerebral haemorrhage over 1381 person-years' follow-up. The proportion with recurrent intracerebral haemorrhage during 5-year follow-up in the intermediate-risk and high-risk CT-only cerebral amyloid angiopathy criteria group was 48 (16%) of 307 patients compared with 21 (8%) of 255 patients in the low-risk group (adjusted sub-distribution hazard ratio [HR] 1·79, 95% CI 1·05-3·05, p=0·032). In the one-stage meta-analysis of the CT-only criteria (1620 patients with lobar intracerebral haemorrhage from eight cohorts, median age 73 years [IQR 62-80], 763 [47%] female and 857 [53%] male), 171 patients had a recurrent intracerebral haemorrhage over 3208 person-years' follow-up. Cumulative 5-year incidence of recurrent intracerebral haemorrhage in the low-risk CT-only cerebral amyloid angiopathy criteria group was 45 (12%) of 727 patients compared with 54 (16%) of 513 patients in the intermediate-risk group (adjusted sub-distribution HR 1·68, 95% CI 1·21-2·32; p=0·0018), and 72 (26%) of 380 patients in the high-risk group (adjusted sub-distribution HR 2·97, 1·50-5·89, p=0·0018). We included six cohorts with 1021 eligible patients for the CT-APOE criteria; 15 patients with missing baseline data were excluded. There were insufficient outcomes in individual CT-APOE cohorts to do the two-stage meta-analysis. In the one-stage meta-analysis of the CT-APOE criteria (1006 patients, median age 71 years [IQR 58-79, 477 [47%] female and 529 [53%] male), 74 patients had a recurrent intracerebral haemorrhage over 1495 person-years' follow-up. Cumulative 3-year incidence of recurrent intracerebral haemorrhage was 34 (15%) of 320 patients in the high-risk CT-APOE cerebral amyloid angiopathy criteria group versus 14 (8%) of 322 patients in the low-risk group (adjusted sub-distribution HR 2·22 [95% CI 1·36-3·61], p=0·0014).The Edinburgh CT-only and CT-APOE diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage were associated with a greater incidence of recurrent intracerebral haemorrhage. These findings could aid personalised prediction and targeted secondary prevention in standard clinical practice where brain CT is available.UK Medical Research Council, The Stroke Association, The Wellcome Trust, and The British Heart Foundation.
000281350 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281350 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281350 650_7 $$2NLM Chemicals$$aApolipoproteins E
000281350 650_2 $$2MeSH$$aHumans
000281350 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: genetics
000281350 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: diagnostic imaging
000281350 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: complications
000281350 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: diagnosis
000281350 650_2 $$2MeSH$$aCerebral Hemorrhage: diagnostic imaging
000281350 650_2 $$2MeSH$$aCerebral Hemorrhage: genetics
000281350 650_2 $$2MeSH$$aCerebral Hemorrhage: etiology
000281350 650_2 $$2MeSH$$aRecurrence
000281350 650_2 $$2MeSH$$aMale
000281350 650_2 $$2MeSH$$aFemale
000281350 650_2 $$2MeSH$$aTomography, X-Ray Computed
000281350 650_2 $$2MeSH$$aAged
000281350 650_2 $$2MeSH$$aMiddle Aged
000281350 650_2 $$2MeSH$$aCohort Studies
000281350 650_2 $$2MeSH$$aAged, 80 and over
000281350 650_2 $$2MeSH$$aApolipoproteins E: genetics
000281350 7001_ $$aSeiffge, David$$b1
000281350 7001_ $$aSamarasekera, Neshika$$b2
000281350 7001_ $$aMoullaali, Tom J$$b3
000281350 7001_ $$aWardlaw, Joanna M$$b4
000281350 7001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b5$$udzne
000281350 7001_ $$aBehymer, Tyler P$$b6
000281350 7001_ $$aKhandwala, Vivek$$b7
000281350 7001_ $$aStanton, Robert J$$b8
000281350 7001_ $$aVagal, Vaibhav$$b9
000281350 7001_ $$aWoo, Daniel$$b10
000281350 7001_ $$aZedde, Marialuisa$$b11
000281350 7001_ $$aPascarella, Rosario$$b12
000281350 7001_ $$aCharidimou, Andreas$$b13
000281350 7001_ $$aWarren, Andrew$$b14
000281350 7001_ $$aGreenberg, Steven M$$b15
000281350 7001_ $$aEppinger, Sebastian$$b16
000281350 7001_ $$aGattringer, Thomas$$b17
000281350 7001_ $$aCasolla, Barbara$$b18
000281350 7001_ $$aCordonnier, Charlotte$$b19
000281350 7001_ $$aWerring, David J$$b20
000281350 7001_ $$aAl-Shahi Salman, Rustam$$b21
000281350 7001_ $$aEdinburgh CAA criteria prognosis collaborators$$b22$$eCollaboration Author
000281350 7001_ $$aAl-Shahi Salman, Rustam$$b23$$eContributor
000281350 7001_ $$aLoan, James J M$$b24$$eContributor
000281350 7001_ $$aMoullaali, Tom J$$b25$$eContributor
000281350 7001_ $$aRodrigues, Mark A$$b26$$eContributor
000281350 7001_ $$aSamarasekera, Neshika$$b27$$eContributor
000281350 7001_ $$aSmith, Colin J$$b28$$eContributor
000281350 7001_ $$aWardlaw, Joanna M$$b29$$eContributor
000281350 7001_ $$aSeiffge, David$$b30$$eContributor
000281350 7001_ $$aWerring, David J$$b31$$eContributor
000281350 7001_ $$0P:(DE-2719)9000797$$aUlbrich, Philipp$$b32$$eContributor$$udzne
000281350 7001_ $$0P:(DE-2719)9000986$$aSchreiber, Frank$$b33$$eContributor$$udzne
000281350 7001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b34$$eContributor$$udzne
000281350 7001_ $$aPascarella, Rosario$$b35$$eContributor
000281350 7001_ $$aZedde, Marialuisa$$b36$$eContributor
000281350 7001_ $$aCharidimou, Andreas$$b37$$eContributor
000281350 7001_ $$aGreenberg, Steven M$$b38$$eContributor
000281350 7001_ $$aWarren, Andrew$$b39$$eContributor
000281350 7001_ $$aBehymer, Tyler$$b40$$eContributor
000281350 7001_ $$aKhandwala, Vivek$$b41$$eContributor
000281350 7001_ $$aStanton, Robert$$b42$$eContributor
000281350 7001_ $$aVagal, Vaibhav$$b43$$eContributor
000281350 7001_ $$aWoo, Daniel$$b44$$eContributor
000281350 7001_ $$aEppinger, Sebastian$$b45$$eContributor
000281350 7001_ $$aGattringer, Thomas$$b46$$eContributor
000281350 7001_ $$aBoulouis, Grégoire$$b47$$eContributor
000281350 7001_ $$aCaparros, François$$b48$$eContributor
000281350 7001_ $$aCasolla, Barbara$$b49$$eContributor
000281350 7001_ $$aCordonnier, Charlotte$$b50$$eContributor
000281350 7001_ $$aDequatre-Ponchelle, Nelly$$b51$$eContributor
000281350 7001_ $$aHénon, Hilde$$b52$$eContributor
000281350 7001_ $$aPuy, Laurent$$b53$$eContributor
000281350 7001_ $$aRossi, Costanza$$b54$$eContributor
000281350 773__ $$0PERI:(DE-600)2079704-7$$a10.1016/S1474-4422(25)00285-6$$gVol. 24, no. 10, p. 828 - 839$$n10$$p828 - 839$$tThe lancet$$v24$$x1474-4422$$y2025
000281350 8564_ $$uhttps://pub.dzne.de/record/281350/files/DZNE-2025-01097%20SUP.pdf
000281350 8564_ $$uhttps://pub.dzne.de/record/281350/files/DZNE-2025-01097.pdf$$yOpenAccess
000281350 8564_ $$uhttps://pub.dzne.de/record/281350/files/DZNE-2025-01097%20SUP.pdf?subformat=pdfa$$xpdfa
000281350 8564_ $$uhttps://pub.dzne.de/record/281350/files/DZNE-2025-01097.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281350 909CO $$ooai:pub.dzne.de:281350$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281350 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000281350 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000797$$aExternal Institute$$b32$$kExtern
000281350 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000986$$aExternal Institute$$b33$$kExtern
000281350 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812631$$aExternal Institute$$b34$$kExtern
000281350 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281350 9141_ $$y2025
000281350 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000281350 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281350 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET NEUROL : 2022$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281350 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bLANCET NEUROL : 2022$$d2024-12-11
000281350 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000281350 9201_ $$0I:(DE-2719)1310010$$kAG Schreiber$$lMixed Cerebral Pathologies and Cognitive Aging$$x0
000281350 980__ $$ajournal
000281350 980__ $$aVDB
000281350 980__ $$aUNRESTRICTED
000281350 980__ $$aI:(DE-2719)1310010
000281350 9801_ $$aFullTexts